BAT7104

Phase 3Biologic

Teva

BAT7104 is one of 26 biologic programs targeting Migraine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

MigrainePhase 3

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Aimovig

Amgen

Preclinical

33 2

Emgality

Eli Lilly

Preclinical

19 3

Vyepti

Lundbeck

Preclinical

12 4

BAT7104

Teva

Phase 3

1 5

Savella

AbbVie

Preclinical

2 6

Bayer Aspirin

Bayer

Preclinical

2 7

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 8

Cervidil

Pfizer

Preclinical

1 9

Viagra

VViatris Specialty LLC

Preclinical

2 10

Pristiq

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Malignant Tumors1 trial

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Completed·BBio-Thera Solutions·Phase 1·NCT05767060·86 enrolled

Migraine1 trial

HARMONY: Fremanezumab Preventive in Episodic Migraine

Active, not recruiting· Teva logo

Teva·Phase 3·NCT05200013·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BAT7104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAT7104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAT7104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Teva

BAT7104

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Malignant Tumors1 trial

Migraine1 trial

References

Drug Info

Quick Facts

Related News